Dr. Bekelman leads research programs in cancer health services and care quality, comparative effectiveness and delivery system and payment reform. His research integrates methods from the fields of epidemiology, clinical trials, health economics and public policy. Dr. Bekelman conducts research to examine the quality, comparative effectiveness, and costs of treatments for prostate, breast, lung and other prevalent cancers using clinical trial, registry, Medicare, and commercial payer administrative claims data. He leads the Radiation Comparative Effectiveness Consortium (RADCOMP) pragmatic randomized clinical trial comparing proton to photon radiation therapy for breast cancer and co-leads the PARTIQoL efficacy randomized clinical trial comparing proton to intensity-modulated radiation therapy (IMRT) for prostate cancer. Dr. Bekelman has received research funding from the National Cancer Institute, the Patient-Centered Outcomes Research Institute, the American Cancer Society, and philanthropic sources. He did his undergraduate work at Princeton University in the Woodrow Wilson School of Public and International Affairs and his medical training at Yale University, Johns Hopkins, and Memorial Sloan Kettering Cancer Center. Previously, he was a management consultant at the Kalchas Group, advising senior executives of health care and insurance clients on corporate strategy. Dr. Bekelman also served as Special Assistant to the Under Secretary of Defense in the US Department of Defense. He is a board-certified radiation oncologist and practicing physician at the University of Pennsylvania Perelman School of Medicine.